Target

FOLH1

Glutamate carboxypeptidase 2

As of the edition of 20 October 2026, FOLH1 (glutamate carboxypeptidase 2, UniProt Q04609) has 27 drugs tested at it and 23 companies on the list, 5 on route A and 4 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q04609
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
90
Disease areas
Cancer; Urinary and reproductive; Pregnancy and women's health; Digestive system; Skin and connective tissue; Chemically induced; Hormones; Injuries
Registered trials of its drugs
171

Drugs at this target

StatusCount
Marketed3
Active7
Went quiet7
Stopped4
Withdrawn from market1
Status not established5
Total27
DrugStatusFurthest phaseUS protection
Vipivotide tetraxetan lutetiumMarketedPhase 4Ends 2036
PiflufolastatMarketedPhase 4Ends 2037
Flotufolastat galliumMarketedPhase 4Ends 2038
FlotufolastatActivePhase 4none listed
J591 177LUStoppedPhase 2none listed
DcfbcWent quietPhase 2none listed
AB-001ActivePhase 2none listed
AcapatamabStoppedPhase 2none listed
FPI-2265ActivePhase 2none listed
IofolastatWent quietPhase 1none listed
CB307Status not establishedPhase 1none listed
MLN-2704Went quietPhase 2none listed

12 of 27 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A5
Route B4
Engaged7
Undetermined7
Total on the list23
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute B
Merck & Co.Route A
Blue Earth DiagnosticsRoute B

The other 20 companies at FOLH1

In the product

23 companies in all; 20 are not named here, and no score is.

See the 23 companies at FOLH1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.